Resources

2015 ESC/ERS PH guidelines
https://academic.oup.com/eurheartj/article/37/1/67/2887599

PHA Europe
https://www.phaeurope.org/

World Symposium on Pulmonary Hypertension (WSPH)
http://www.wsphassociation.org/

Uptravi^® Israel PI
https://data.health.gov.il/drugs/index.html#!/byDrug

Learn More About UPTRAVI^®

.gbi-622321773-eGyqHc4yMPCH4XbDM7yky1:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt45e2500ac865eed4/bltd3daafd425964278/612cbec8ea454059dd394697/Uptravi-Interest-Callout-Background.jpg?width=600&height=338&format=jpg&quality=50''); }

Studies

Details of the GRIPHON study, where the safety and efficacy of UPTRAVI^® were investigated in a Phase 3 study to assess the long-term benefits for pulmonary arterial hypertension (PAH) patients.

.gbi-622321773-4mDswVwdLViPDvoLZTRC6Y:before { opacity: 1; background-image: url(''https://eu-images.contentstack.com/v3/assets/blt45e2500ac865eed4/bltd3daafd425964278/612cbec8ea454059dd394697/Uptravi-Interest-Callout-Background.jpg?width=600&height=338&format=jpg&quality=50''); }

Product Overview

A synopsis of the key benefits of UPTRAVI^® in the treatment of PAH.

EM- 50402

Resources

Learn More About UPTRAVI®

Studies

Product Overview

Learn More About UPTRAVI^®